Relay Therapeutics, Inc. (RLAY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Relay Therapeutics, Inc. (RLAY) trades at $19.70 with AI Score 24/100 (Grade F). Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery in targeted oncology and genetic disease indications. Market cap: $4.32B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026RLAY stock analysis for 2026: Analysts have set a consensus price target of $18.00 for Relay Therapeutics, Inc., suggesting 8.6% downside from the current price of $19.70. The AI MoonshotScore is 24/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RLAY: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Relay Therapeutics, Inc. (RLAY) Healthcare & Pipeline Overview
Relay Therapeutics is a clinical-stage biotechnology firm pioneering precision medicines through advanced computational techniques, targeting oncology and genetic diseases. Their innovative approach to small molecule drug discovery, coupled with strategic collaborations, positions them uniquely within the competitive biopharmaceutical landscape, addressing significant unmet medical needs.
What Is the Investment Thesis for RLAY?
Relay Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative approach to drug discovery and promising clinical pipeline. The company's focus on precision medicines, particularly in targeted oncology, addresses a significant unmet medical need. Key value drivers include the advancement of RLY-4008 through clinical trials, with potential for accelerated approval based on early efficacy data. The ongoing Phase 1 trial of RLY-1971 and the development of RLY-2608 also contribute to the company's growth prospects. However, the investment is subject to risks inherent in clinical-stage biotechnology companies, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $4.32B and a negative profit margin of -2554.1%, Relay Therapeutics' financial performance is heavily dependent on the successful development and commercialization of its drug candidates. The company's high beta of 1.58 indicates higher volatility compared to the market, reflecting the speculative nature of biotechnology investments. Successful execution of clinical programs and strategic partnerships will be critical for realizing the company's long-term value.
Based on FMP financials and quantitative analysis
RLAY Key Highlights
Market Cap of $4.32B reflects investor confidence in Relay Therapeutics' pipeline and precision medicine approach.
- Gross Margin of 89.7% indicates strong potential profitability upon successful commercialization of drug candidates.
- Profit Margin of -2554.1% highlights the significant R&D investment typical of clinical-stage biotechnology companies.
- Lead product candidate RLY-4008 is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors, representing a key milestone.
- Collaboration with Genentech, Inc. for the development and commercialization of RLY-1971 validates Relay Therapeutics' technology and approach.
Who Are RLAY's Competitors?
RLAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARRY Array Technologies, Inc. | $4.71 | -4.27% | $725M | — |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| AMLX Amylyx Pharmaceuticals, Inc. | $39.66 | +2.75% | $4.41B | 70 |
| ELVN Enliven Therapeutics, Inc. | $58.92 | -0.79% | $4.21B | 79 |
| CPRX Catalyst Pharmaceuticals, Inc. | $31.49 | +0.00% | $3.85B | 99 |
| ACAD ACADIA Pharmaceuticals Inc. | $29.15 | -3.51% | $4.99B | 89 |
| ABCL AbCellera Biologics Inc. | $11.57 | -3.66% | $3.53B | 76 |
| VCYT Veracyte, Inc. | $41.79 | -0.95% | $3.33B | 96 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RLAY's Key Strengths?
Innovative drug discovery platform integrating computational and experimental approaches.
- Promising pipeline of targeted therapies in clinical development.
- Strategic collaborations with leading pharmaceutical companies.
- Strong intellectual property portfolio.
What Are RLAY's Weaknesses?
Clinical-stage company with no currently marketed products.
- High R&D expenses and negative profit margins.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Competition from established pharmaceutical companies and other biotech firms.
What Could Drive RLAY Stock Higher?
RLAY catalyst: Data readouts from the Phase 1 clinical trial of RLY-1971 in patients with advanced solid tumors.
- Initiation of Phase 2 clinical trials for RLY-4008 in FGFR2-altered solid tumors.
- Enrollment and progression of patients in the first-in-human clinical trial of RLY-4008.
- Continued development and optimization of RLY-2608 targeting mutant-PI3Ka.
What Are the Key Risks for RLAY?
Negative return on equity (-43.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in the development of Relay Therapeutics' drug candidates.
- Regulatory setbacks or changes in the regulatory landscape.
- Competition from other targeted therapies and established pharmaceutical companies.
- High R&D expenses and negative profit margins.
- Dependence on successful collaborations with partners like Genentech.
What Are the Growth Opportunities for RLAY?
- Expansion of RLY-4008 into Additional FGFR2-Altered Tumor Types: RLY-4008, currently in Phase 1 trials for FGFR2-altered solid tumors, has the potential to expand into other tumor types harboring FGFR2 alterations. This expansion could significantly increase the addressable patient population and market opportunity. The FGFR2 inhibitor market is projected to grow as precision medicine advances, offering Relay Therapeutics a substantial growth avenue. Success in these trials and subsequent regulatory approvals could drive significant revenue growth.
- Advancement of RLY-2608 Targeting Mutant-PI3Ka: RLY-2608, a mutant-PI3Ka inhibitor, represents a significant growth opportunity in addressing cancers driven by PI3K mutations. The PI3K pathway is frequently dysregulated in various cancers, making it a high-value drug target. Positive clinical data and regulatory approval could position RLY-2608 as a key therapy in this space, capturing a significant share of the PI3K inhibitor market. This market is expected to expand as more precise diagnostic tools identify patients who could benefit from PI3K-targeted therapies.
- Development and Commercialization of RLY-1971 Through Genentech Collaboration: The collaboration with Genentech for RLY-1971 provides Relay Therapeutics with a strong partner for development and commercialization. RLY-1971, an SHP2 inhibitor, targets a key signaling pathway in cancer. Genentech's expertise and resources can accelerate the development and market penetration of RLY-1971, generating milestone payments and royalties for Relay Therapeutics. This partnership de-risks the development process and provides a pathway to commercial success.
- Expansion into New Therapeutic Areas Beyond Oncology: While Relay Therapeutics' initial focus is on oncology, the company's platform and expertise in precision medicine can be leveraged to expand into other therapeutic areas, such as genetic diseases and autoimmune disorders. These areas represent significant unmet medical needs and market opportunities. By applying its computational modeling and drug discovery capabilities to new targets, Relay Therapeutics can diversify its pipeline and revenue streams, reducing its reliance on oncology-specific products.
- Strategic Partnerships and Acquisitions to Expand Pipeline: Relay Therapeutics can pursue strategic partnerships and acquisitions to expand its pipeline and access new technologies. Collaborating with or acquiring companies with complementary expertise or promising drug candidates can accelerate the company's growth and enhance its competitive position. These partnerships can provide access to new targets, technologies, and markets, driving long-term value creation.
What Are RLAY's Competitive Advantages?
- Proprietary computational platform for drug discovery: Relay Therapeutics' platform integrates advanced computational techniques, including protein motion analysis, to design novel therapies.
- Strong intellectual property portfolio: The company has patents covering its drug candidates and platform technologies.
- Strategic collaborations with leading pharmaceutical companies: Partnerships with companies like Genentech provide access to resources and expertise.
- Focus on precision medicine: Relay Therapeutics' focus on targeted therapies addresses a growing market need.
What Does RLAY Do?
Relay Therapeutics, Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a clinical-stage precision medicines company focused on transforming the drug discovery process. The company was initially known as Allostery, Inc., before rebranding to Relay Therapeutics to better reflect its mission. Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery, particularly in targeted oncology and genetic disease indications. Their core strategy involves integrating advanced computational techniques, including protein motion analysis, to design and develop novel therapies. Relay Therapeutics' pipeline includes several promising product candidates. RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), is currently in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors. RLY-2608 is a lead mutant-PI3Ka inhibitor program targeting phosphoinostide 3 kinase alpha. RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase SHP2, is in Phase 1 trial for patients with advanced solid tumors. These programs reflect the company's commitment to developing targeted therapies that address specific genetic mutations and signaling pathways driving disease progression. Relay Therapeutics has established strategic collaborations to support its research and development efforts. A collaboration and license agreement with D. E. Shaw Research, LLC allows Relay to leverage computational modeling capabilities focused on protein motion analysis to discover and develop compounds. Another collaboration with Genentech, Inc. focuses on the development and commercialization of RLY-1971, highlighting the company's ability to attract partnerships with leading pharmaceutical companies. With a focus on precision medicine and a robust pipeline, Relay Therapeutics aims to deliver transformative therapies for patients with cancer and genetic diseases.
What Products and Services Does RLAY Offer?
- Develops precision medicines targeting specific genetic mutations and signaling pathways.
- Utilizes advanced computational techniques, including protein motion analysis, to design novel therapies.
- Focuses on small molecule drug discovery for targeted oncology and genetic disease indications.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with leading pharmaceutical companies and research institutions to advance its pipeline.
- Aims to transform the drug discovery process by integrating computational and experimental approaches.
- Develops oral small molecule inhibitors for various cancer targets.
How Does RLAY Make Money?
- Develops and patents novel drug candidates targeting specific disease-causing proteins.
- Out-licenses or co-develops drug candidates with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments, royalties on sales of commercialized products, and direct sales of approved drugs.
- Invests heavily in research and development to discover and advance new drug candidates.
What Industry Does RLAY Operate In?
Relay Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The precision medicine market, estimated to reach $141.83 billion by 2032, is a key growth area, driven by advancements in genomics and targeted therapies. Relay Therapeutics' focus on small molecule drug discovery and computational modeling positions it to capitalize on this trend. The company competes with both large pharmaceutical companies and smaller biotech firms developing targeted therapies for oncology and genetic diseases. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Who Are RLAY's Key Customers?
- Patients with advanced or metastatic solid tumors harboring specific genetic alterations (e.g., FGFR2 alterations).
- Oncologists and other healthcare professionals who prescribe targeted therapies.
- Pharmaceutical companies that partner with Relay Therapeutics to develop and commercialize drug candidates.
- Hospitals and cancer centers that use Relay Therapeutics' drugs to treat patients.
Company Profile
Relay Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Sanjiv K. Patel. RLAY has traded publicly since 2020.
How Relay Therapeutics, Inc. Is Valued
Relay Therapeutics, Inc. carries a market capitalization of $4.32B, placing it in the mid-cap category. Relative to its peer group, RLAY's quantitative score of 24/100 is below the peer average of 75/100.
Key Financial Metrics
Return on equity for Relay Therapeutics, Inc. stands at -43.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Relay Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 32.19 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Relay Therapeutics, Inc. revenue of about $11.8M for fiscal 2026, with EPS near $-1.55. The estimate reflects 9 contributing analysts.
RLAY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Relay's focus on precision medicine is gaining traction, with potential for groundbreaking therapies. Think of it like Moderna's early days, before mRNA tech fully proved out.
- Insider buying suggests confidence in Relay's long-term prospects, echoing similar moves before Amgen's major acquisitions.
- Community sentiment reflects optimism about upcoming clinical trial results, similar to excitement around CRISPR stocks pre-breakthroughs.
- The market is starting to recognize the value of Relay's unique approach to drug discovery, much like investors warmed up to Regeneron's antibody platform.
Bear Case
- The biotech sector is highly volatile; Relay could face unexpected setbacks, similar to Biogen's Aduhelm controversy.
- Community discussions reveal concerns about competition from larger pharmaceutical companies, like the pressures faced by smaller players against Pfizer.
- Recent market events have created a risk-off environment, potentially impacting Relay's funding and valuation, mirroring the effects of the 2008 crisis on emerging tech.
- There's skepticism about the timeline for Relay's drugs to reach the market, akin to the long wait times for Vertex's cystic fibrosis treatments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RLAY Latest News
No recent news available for RLAY.
RLAY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RLAY.
Price Targets
Consensus target: $18.00
RLAY MoonshotScore
What does this score mean?
The MoonshotScore rates RLAY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Relay Therapeutics, Inc. Analysis
Leadership: Sanjiv K. Patel
Chief Executive Officer
Sanjiv K. Patel serves as the Chief Executive Officer of Relay Therapeutics, bringing extensive experience in the biopharmaceutical industry. Prior to joining Relay, he held leadership positions at Allergan, where he oversaw strategic initiatives and business development. His background includes a strong focus on oncology and specialty pharmaceuticals, with a track record of driving growth and innovation. Patel holds an MBA from the Wharton School of the University of Pennsylvania and a Bachelor of Science degree in Biology from the University of Michigan.
Track Record: Under Sanjiv K. Patel's leadership, Relay Therapeutics has advanced its pipeline of precision medicines, including the progression of RLY-4008 into clinical trials. He has also overseen strategic collaborations, such as the partnership with Genentech, to accelerate the development and commercialization of the company's drug candidates. Patel's tenure has been marked by a focus on building a strong scientific team and advancing Relay Therapeutics' position in the precision medicine field.
Common Questions About RLAY (Healthcare)
What does the AI Score mean for RLAY?
RLAY holds an AI Score of 24/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery in targeted oncology and genetic disease indications. Their approach enhances small …
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming drug discovery in targeted oncology and genetic disease indications. The company utilizes advanced computational techniques, including protein motion analysis, to design and develop novel small molecule therapies. Relay's lead product candidates include RLY-4008, an FGFR2 inhibitor; RLY-2608, a mutant-PI3Ka inhibitor; and RLY-1971, an SHP2 inhibitor.
What do analysts say about RLAY stock?
Analyst coverage of Relay Therapeutics (RLAY) reflects a generally optimistic outlook, driven by the company's innovative drug discovery platform and promising clinical pipeline. Key valuation metrics include price targets based on discounted cash flow analysis, reflecting the potential future revenue from successful drug commercialization.
What are the main risks for RLAY?
Relay Therapeutics faces several key risks inherent in its business model as a clinical-stage biotechnology company. A primary risk is the potential for clinical trial failures, which could significantly impact the company's pipeline and valuation. Regulatory setbacks, such as delays in approval or rejection of drug candidates, also pose a significant risk.
What are the key factors to evaluate for RLAY?
Relay Therapeutics, Inc. (RLAY) holds an AI score of 24/100 (low). Analysts target $18.00 (-9%). Relay Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative approach to drug discovery and promising clinical pipeline. Not financial advice.
How frequently does RLAY data refresh on this page?
RLAY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RLAY's recent stock price performance?
Relay Therapeutics, Inc. (RLAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug discovery platform integrating computational and experimental approaches. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RLAY overvalued or undervalued right now?
Relay Therapeutics, Inc. (RLAY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $18.00 (-9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RLAY before investing?
Before investing in Relay Therapeutics, Inc. (RLAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.